That is the title of my Fast Facts presentation at ISPOR Europe at 11:30 GMT on Tuesday, November 11 with Tiago Beck. If you’re in Glasgow next week, feel free to stop by this session. Should be interesting. The abstract is below.
As trilogue negotiations on the EU pharmaceutical package progress, stakeholders across the healthcare ecosystem are watching closely. This revision aims to reshape incentives, regulatory pathways, and access mechanisms across Europe—with direct implications for payers, HTA bodies, industry, and patients. In this fast facts session, we’ll unpack where the legislative process currently stands and the key issues shaping the final compromise. Areas of focus include: 1) progress and timelines in the trilogue phase; 2) potential impacts on data and market protection; 3) revised incentives for orphan and pediatric medicines; 4) the interplay with EU industrial and competitiveness goals; and 5) potential implications for national-level pricing, reimbursement, and access. With critical decisions ahead, this session offers a concise policy snapshot for understanding where the EU pharma package is headed and why it matters for health economists and payers alike.
Full session details here.
Disclaimer :
This article is solely for informational purposes, any medical information contained is not a substitute for professional medical advice and readers should not rely on it as such.
If you believe there may be errors or misinformation in this article, we encourage you to contact the webmasters by messaging the provided contact information.
Your feedback is valuable, and we are committed to rectifying any inaccuracies. Please note that the content will be re-evaluated, and corrections will be made as necessary following your submission.